Literature DB >> 25781697

Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.

Pierpaolo Trimboli, Luca Giovanella.   

Abstract

Generally, calcitonin (CT) values below the upper reference limit rule-out medullary thyroid carcinoma (MTC) with very high accuracy. However, sparse cases of serum-calcitonin-negative MTC (CT-NEG-MTC) have been reported. Here we reviewed CT-NEG-MTC reported in literature, discussed the potential causes and proposed a practical laboratory and clinical approach. A comprehensive literature search was conducted by using the terms "medullary thyroid carcinoma" AND "non-secreting calcitonin" OR "undetectable calcitonin". The search was updated until December 2014. Original articles that described CT-NEG-MTC were eligible for inclusion. Only MTC cases with preoperative CT below the upper reference limit were included in the present review. Eleven papers with 18 CT-NEG-MTC cases (age 50 years, size 26 mm) were retrieved. Four patients with poorly differentiated MTC died within 3 years. Different CT assays were employed and different reference values were adopted. Preoperative serum CT values were below the institution cut-off levels in all cases, and undetectable in four patients. In some papers negative CT results were confirmed by additional tests. Further laboratory investigations were performed in some of the included studies. In patients with well founded suspicious of MTC and within the reference limits/undetectable CT other laboratory investigations [carcinoembryonic antigen (CEA), procalcitonin, CT stimulation, CT in washout of nodule's aspiration] have to be performed. Surgical approach to CT-NEG-MTC does not differ from those secreting CT. Postoperative follow-up of these rare cases should include periodical imaging and measurement of all potential markers. Patients with poorly differentiated MTC are at higher risk of disease-related death, and require more aggressive follow-up strategy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25781697     DOI: 10.1515/cclm-2015-0058

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  13 in total

1.  Calcitonin-negative medullary thyroid carcinoma: the 'triple-negative' phenotype.

Authors:  D C Murphy; S J Johnson; S Aspinall
Journal:  Ann R Coll Surg Engl       Date:  2019-12-16       Impact factor: 1.891

2.  EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.

Authors:  Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

3.  Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer.

Authors:  Fernanda Andrade; Geneviève Rondeau; Laura Boucai; Rebecca Zeuren; Ashok R Shaha; Ian Ganly; Fernanda Vaisman; Rossana Corbo; Michael Tuttle
Journal:  Arch Endocrinol Metab       Date:  2019-03-21       Impact factor: 2.309

Review 4.  Clinical challenges with calcitonin-negative medullary thyroid carcinoma.

Authors:  Maria Teresa Samà; Ruth Rossetto Giaccherino; Marco Gallo; Francesco Felicetti; Francesca Maletta; Nadia Bonelli; Alessandro Piovesan; Nicola Palestini; Ezio Ghigo; Emanuela Arvat
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-28       Impact factor: 4.553

5.  Pediatric Medullary Thyroid Carcinoma.

Authors:  Dmytro Starenki; Jong-In Park
Journal:  J Pediatr Oncol       Date:  2015

6.  Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Luca Giovanella
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06

Review 7.  Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.

Authors:  Claudio Gambardella; Chiara Offi; Guglielmo Clarizia; Roberto Maria Romano; Immacolata Cozzolino; Marco Montella; Rosa Maria Di Crescenzo; Massimo Mascolo; Angelo Cangiano; Sergio Di Martino; Giancarlo Candela; Giovanni Docimo
Journal:  BMC Endocr Disord       Date:  2019-10-16       Impact factor: 2.763

8.  Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules.

Authors:  Luca Giovanella; Mauro Imperiali; Arnoldo Piccardo; Monica Taborelli; Frederik Anton Verburg; Federica Daurizio; Pierpaolo Trimboli
Journal:  Eur J Clin Invest       Date:  2018-04-20       Impact factor: 4.686

9.  Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review.

Authors:  Li Chen; Ke Zhao; Fuxin Li; Xianghui He
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

10.  Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma.

Authors:  Arezou A Ghazani; Katelyn M Breen; Meaghan Dwan; Justine A Barletta; Donna R Vatnick; Samantha M Stokes; Caroline Block; Gerard M Doherty; Aviva Y Cohn; Ellen Marqusee; Judy E Garber; Huma Q Rana
Journal:  Am J Case Rep       Date:  2020-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.